These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


366 related items for PubMed ID: 20547037

  • 21. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, De Persis S, Piazzi G, Simonetti A, Telesforo CL, Sciarretta A, Caccia F, Gentile G, Kotzalidis GD, Girardi P.
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [Abstract] [Full Text] [Related]

  • 22. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO.
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.
    Suppes T, Eudicone J, McQuade R, Pikalov A, Carlson B.
    J Affect Disord; 2008 Apr; 107(1-3):145-54. PubMed ID: 17904226
    [Abstract] [Full Text] [Related]

  • 24. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
    Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, McQuade RD, Carson WH, CN138-135 Study Group.
    J Affect Disord; 2009 Jan; 112(1-3):36-49. PubMed ID: 18835043
    [Abstract] [Full Text] [Related]

  • 25. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
    Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group.
    J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
    [Abstract] [Full Text] [Related]

  • 26. Intramuscular aripiprazole in the control of agitation.
    Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, Pikalov AA, Crandall DT.
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [Abstract] [Full Text] [Related]

  • 27. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR.
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, McQuade R, Pikalov AA, Crandall DT.
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [Abstract] [Full Text] [Related]

  • 29. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, Bose A, Silverman BL, Ehrich EW.
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [Abstract] [Full Text] [Related]

  • 30. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [Abstract] [Full Text] [Related]

  • 31. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S.
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [Abstract] [Full Text] [Related]

  • 32. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
    Cipriani A, Accordini S, Nosè M, Purgato M, Girlanda F, Tansella M, Barbui C.
    J Clin Psychopharmacol; 2013 Aug; 33(4):533-7. PubMed ID: 23775051
    [Abstract] [Full Text] [Related]

  • 33. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, Perry PP, Gara M, McQuade RD, Carson WH, Sanchez R.
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [Abstract] [Full Text] [Related]

  • 34. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T, Samalin L, Llorca PM.
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.
    Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
    [Abstract] [Full Text] [Related]

  • 36. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Correll CU, Zhao J, Carson W, Marcus R, McQuade R, Forbes RA, Mankoski R.
    J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
    [Abstract] [Full Text] [Related]

  • 37. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
    Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT.
    J Clin Psychiatry; 2007 May; 68(5):662-8. PubMed ID: 17503974
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
    Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA.
    J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
    [Abstract] [Full Text] [Related]

  • 39. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.
    Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A.
    Appl Health Econ Health Policy; 2009 Jan; 7(2):109-19. PubMed ID: 19731968
    [Abstract] [Full Text] [Related]

  • 40. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T.
    Schizophr Res; 2003 Jun 01; 61(2-3):123-36. PubMed ID: 12729864
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 19.